J&J gets approval to buy Synthes, as EC accepts its commitment to sell trauma business
The European Commission has approved Johnson & Johnson’s proposed acquisition of Synthes, subject to J&J selling their trauma business. Johnson & Johnson had submitted commitments to selling their European trauma device business, given the Commission’s findings of J&J and Synthes’ market shares and the reluctance of surgeons in switching suppliers.
Following an investigation into the market for orthopedic medical devices, the Commission found that strong competitors for spine, shoulder replacement and cranio-maxillofacial devices would remain after the transaction.
Full content: EC Press Release
Related content: Analyzing Medical Device Mergers
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI